Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

NCT03141034 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03141034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03141034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2017
Completion date
April 14, 2023
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastro-esophageal junction adenocarcinoma